How do I buy Inventiva S.A. American Depository Shares (IVA) stock?

Buying Inventiva S.A. American Depository Shares (IVA) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "IVA", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy IVA by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for IVA on Gotrade?

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Inventiva S.A. American Depository Shares from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Inventiva S.A. American Depository Shares (IVA) pay dividends?

At the moment, Inventiva S.A. American Depository Shares (IVA) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track IVA's performance via the price chart in the Gotrade app.

Is buying IVA on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy IVA?

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours. Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

How do I tell if IVA is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Inventiva S.A. American Depository Shares (IVA) Stock Price Today & Analysis

% positive news of 6 articles

published over the past 14 days

Latest news

Zacks Investment Research

After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Inventiva (IVA)

NeutralIVAJune 29, 2026

Zacks Investment ResearchNeutral

After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Inventiva (IVA)

IVA

Zacks Investment Research

Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround

NeutralIVAJune 11, 2026

Zacks Investment ResearchNeutral

Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround

IVA

Zacks Investment Research

Does Inventiva (IVA) Have the Potential to Rally 136.34% as Wall Street Analysts Expect?

NeutralIVAFebruary 27, 2026

Zacks Investment ResearchNeutral

Does Inventiva (IVA) Have the Potential to Rally 136.34% as Wall Street Analysts Expect?

IVA

Reuters

Wall Street Analysts Predict a 200.59% Upside in Inventiva (IVA): Here's What You Should Know

NeutralIVAJanuary 8, 2026

Zacks Investment ResearchNeutral

Wall Street Analysts Predict a 200.59% Upside in Inventiva (IVA): Here's What You Should Know

IVA

About Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

SectorHealthcare

IndustryBiotechnology

Employees69

CEOMr. Andrew Obenshain

IPO DateJul 10, 2020

HeadquartersDaix, France

Key Executives

Name	Title	Year Born
Mr. Andrew Obenshain	Chief Executive Officer	1974
Dr. Pierre Broqua Ph.D.	Co-Founder	1962
Mr. Jean Volatier	Executive VP Finance & Corporate Social Responsibility	1965
Dr. Martine Zimmermann Pharm.D.	Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs	1969
Mr. Jason A. Campagna M.D., Ph.D.	President of Research & Development and Chief Medical Officer	1966
Mr. Axel-Sven Malkomes	Chief Financial Officer	1967
Ms. Susan Coles	Chief Legal Officer	1966
Ms. Pamela Herbster	Chief People Officer	—
Ms. Nazira Amra M.D.	Chief Commercial Strategy Officer	—

Fundamentals

Valuation

Market cap$796.11M

Price-to-sales ratio67.56

Price-to-book value-18.77

Price-earnings ratio-1.50

Return on EquityN/A

Return on SalesN/A

Return on AssetsN/A

PEG ratioN/A

Earnings Per Share

Earnings Per Share$-2.24

Income Statement

Average volume1,449,426

EBITDA$-157.61M

1 year high (52w)$7.98

1 year low (52w)$3.11

Dividend

Ex dividend dateN/A

Dividend amount$0.00

Dividend yield0.00%

Last payment dateN/A

Dividend yield (TTM)N/A

Next earnings reportN/A

Solvency

Debt-to-equity ratioN/A

Technicals

OscillatorsSell5 Indicators

Moving AveragesStrong Sell12 Indicators

What the experts say

2 Wall Street Analyst Ratings

BUY

100% Buy

0% Hold

0% Sell

Target price

$14.00

Est return

309.96%

Guggenheim

Seamus Fernandez

Buy

Target price

$14.00

Est return

309.96%

Cantor Fitzgerald

Prakhar Agrawal

Buy

Target price

$0.00

Est return

100.00%

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2026	-2.5	+9.8	-11.8	-5.5	-0.8	-20.8	+21.4	+10.1	-29.4

Inventiva S.A. American Depository Shares (IVA) Stock

Fundamentals

Recent news

After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Inventiva (IVA)

After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Inventiva (IVA)

Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround

Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround

Does Inventiva (IVA) Have the Potential to Rally 136.34% as Wall Street Analysts Expect?

Does Inventiva (IVA) Have the Potential to Rally 136.34% as Wall Street Analysts Expect?

Biotech Inventiva's 50% surge shows investor optimism over liver disease drug

Biotech Inventiva's 50% surge shows investor optimism over liver disease drug

Technicals

Analyst Ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Inventiva (IVA)

After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Inventiva (IVA)

Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround

Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround

Does Inventiva (IVA) Have the Potential to Rally 136.34% as Wall Street Analysts Expect?

Does Inventiva (IVA) Have the Potential to Rally 136.34% as Wall Street Analysts Expect?

Biotech Inventiva's 50% surge shows investor optimism over liver disease drug

Biotech Inventiva's 50% surge shows investor optimism over liver disease drug

Are You Looking for a Top Momentum Pick? Why Inventiva S.A.

Are You Looking for a Top Momentum Pick? Why Inventiva S.A.

Wall Street Analysts Predict a 200.59% Upside in Inventiva (IVA): Here's What You Should Know

Wall Street Analysts Predict a 200.59% Upside in Inventiva (IVA): Here's What You Should Know

About Inventiva S.A. American Depository Shares

Key Executives

Fundamentals

Valuation

Earnings Per Share

Income Statement

Dividend

Solvency

Technicals

What the experts say

Seasonality

FAQ

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade